KRAS and colorectal carcinoma: While KRAS mutations, which occur predominantly at codons 12 (G12) and 13 (G13) in CRC, were previously thought to be undruggable, recent efforts have led to the development of several small‐molecule inhibitors such as the G12C inhibitors sotorasib and adagrasib as well as the G12D inhibitor MTRX1133 [14].